Ponatinib-blinatumomab lifts 2-year EFS to 86% in Ph+ ALL

Editor's Pick: Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL (New England Journal of Medicine, 2026)
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning chemotherapy-free and transplant-sparing strategies in blood cancers, de-escalation and refinement in early breast cancer, and the expanding, sometimes sobering, reach of precision and immune therapy in solid tumors. Let's dive in.
This week's papers:
• Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL. — New England Journal of Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42874102)
• First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Malignancies. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42879732)
• Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III Trial. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42896129)
• Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial. — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42887596)
• DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer. — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42870529)
• Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations. — Cancer Cell 2026 (pubmed.ncbi.nlm.nih.gov/42887497)
• Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42874021)
• Treatment of Advanced Biliary Tract Cancer: ASCO Living Guideline, Version 2026.1.0. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42874012)
• Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial. — Nature Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42875559)
• Nivolumab-Ipilimumab for Localized Microsatellite Instability-High Gastric/Gastroesophageal Junction Adenocarcinoma: The Phase 2 NEONIPIGA Nonrandomized Clinical Trial. — JAMA Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42879140)
Listen at AudioScholar (audioscholar.cc/episode/qycvs4rbnr)